Aurora Cannabis Inc. (ACB): Modelo de negócios Canvas [Jan-2025 Atualizado]

A Aurora Cannabis Inc. (ACB) fica na vanguarda de uma revolucionária transformação da indústria de cannabis, posicionando -se estrategicamente como líder global por meio de um modelo de negócios inovador e abrangente. Ao integrar perfeitamente tecnologias avançadas de cultivo, pesquisa médica e diversas ofertas de produtos, a Aurora criou uma abordagem dinâmica que abrange os mercados de cannabis médicos e recreativos em vários territórios internacionais. Sua tela de modelo de negócios meticulosamente projetada revela um complexo ecossistema de parcerias, recursos e proposições de valor que as distinguem em um cenário cada vez mais competitivo, prometendo potenciais investidores e consumidores um vislumbre de uma empresa de cannabis sofisticada e que pensa avançada.

Aurora Cannabis Inc. (ACB) - Modelo de negócios: Parcerias -chave

Produtores e distribuidores de cannabis licenciados

A Aurora Cannabis estabeleceu parcerias estratégicas com os seguintes produtores licenciados:

Parceiro	Detalhes da parceria	Ano estabelecido
Alcanna Inc.	Colaboração de distribuição de cannabis de varejo	2018
Nelson Hemp Company	Cultivo de cânhamo e parceria de processamento	2019

Fornecedores de Equipamentos de Tecnologia Agrícola e Cultivo

As principais parcerias de tecnologia e equipamentos incluem:

• Fazendas de fótons - Sistemas de iluminação de cultivo LED
• MJ Technologies - Equipamento de monitoramento de cultivo automatizado
• Soluções de Automação de Cannagrow - Sistemas de Controle Ambiental de Greenhouse

Instituições de pesquisa médica e universidades

Instituição	Foco na pesquisa	Tipo de colaboração
Universidade de Toronto	Pesquisa de aplicações médicas de cannabis	Parceria do Estudo Clínico
Universidade McGill	Potencial terapêutico canabinóide	Pesquisa concede colaboração

Redes de dispensários de cannabis de varejo

As parcerias de dispensários de varejo da Aurora incluem:

• Meta Cannabis Supply Co. - 17 locais de varejo em Saskatchewan
• Nova Cannabis - 24 lojas de varejo em várias províncias
• Choom Holdings - Colaboração de rede de varejo de cannabis

Parceiros internacionais de expansão do mercado de cannabis

País	Parceiro	Estratégia de entrada de mercado
Alemanha	Espectro cannabis gmbh	Distribuição de cannabis medicinal
Austrália	Cannatrek Limited	Parceria de cultivo e exportação
Uruguai	Consórcio de Cannabis de Montevidideo	Produção e distribuição local

Aurora Cannabis Inc. (ACB) - Modelo de negócios: Atividades -chave

Cultivo e produção de cannabis em larga escala

A Aurora Cannabis opera várias instalações de cultivo com uma capacidade total licenciada de aproximadamente 660.000 kg por ano. Os locais de produção primários da empresa incluem:

Nome da instalação	Localização	Capacidade de cultivo
Aurora Sky	Edmonton, Alberta	100.000 kg anualmente
Aurora Mountain	Calgary, Alberta	40.000 kg anualmente
Medreleaf Bradford	Ontário	35.000 kg anualmente

Pesquisa e desenvolvimento de produtos de cannabis medicinal

A Aurora Cannabis investiu US $ 38,7 milhões em despesas de pesquisa e desenvolvimento no ano fiscal de 2023. As principais áreas de foco em P&D incluem:

• Formulações de cannabis medicinal
• Tecnologias de extração de canabinóides
• Parcerias de pesquisa clínica

Inovação de produtos e desenvolvimento de tensão

A empresa mantém uma biblioteca genética proprietária com mais de 500 cepas exclusivas de cannabis. Orçamento anual de desenvolvimento de produtos: US $ 12,5 milhões.

Conformidade regulatória e controle de qualidade

Métrica de conformidade	Status
Licenças Health Canada	8 Cultivo ativo e licenças de processamento
Equipe de garantia de qualidade	52 profissionais de conformidade dedicados
Gastos anuais de conformidade	US $ 6,2 milhões

Expansão do mercado internacional e aquisições estratégicas

A Aurora Cannabis concluiu 15 aquisições internacionais em 8 países, com um investimento total de US $ 487 milhões em expansão do mercado internacional.

• Presença operacional no Canadá, Alemanha, Itália, Dinamarca
• Redes de distribuição no Uruguai, Austrália
• Parcerias estratégicas em mercados de cannabis medicinal

Aurora Cannabis Inc. (ACB) - Modelo de negócios: Recursos -chave

Instalações avançadas de estufa e cultivo interno

A Aurora Cannabis opera várias instalações de cultivo licenciadas em todo o Canadá, totalizando aproximadamente 1,62 milhão de pés quadrados de capacidade de produção em 2023.

Localização da instalação	Capacidade de produção (Sq ft)
Aurora Sky (Edmonton, Alberta)	800,000
Aurora Mountain (Medicine Hat, Alberta)	250,000
Aurora Vie (Quebec)	170,000

Programas proprietários de genética e criação de cannabis

Portfólio de propriedade intelectual:

• Mais de 500 patentes emitidas e pendentes em todo o mundo
• Programas de reprodução especializados com foco em cepas de alto e alto-CBD
• Repositório genético com mais de 260 cultivares de cannabis exclusivas

Força de trabalho científica e agrícola qualificada

A partir de 2023, a Aurora Cannabis emprega aproximadamente 1.200 profissionais em pesquisas, cultivos e papéis operacionais.

Categoria profissional	Número de funcionários
Cientistas de pesquisa	85
Especialistas agrícolas	320
Operações e gerenciamento	795

Portfólio de propriedade intelectual

Os principais ativos de propriedade intelectual incluem:

• Patente para tecnologia de nano-emulsão
• Métodos proprietários de extração de cannabis
• Técnicas avançadas de cultivo

Infraestrutura de distribuição e cadeia de suprimentos

A Aurora Cannabis mantém recursos de distribuição em várias províncias canadenses e mercados internacionais.

Canal de distribuição	Alcance do mercado
Cannabis medicinal	12 países
Cannabis de uso adulto	Províncias canadenses
Exportação Internacional	5 países

Aurora Cannabis Inc. (ACB) - Modelo de negócios: proposições de valor

Produtos de cannabis médicos e recreativos de alta qualidade

A Aurora Cannabis produz produtos de cannabis com as seguintes especificações:

Categoria de produto	Thc porcentagem	Porcentagem de CBD	Capacidade de produção anual
Flor de cannabis seca	15-25%	0.5-2%	75.000 kg por ano
Óleos de cannabis	10-90%	5-50%	40.000 kg por ano

Gama diversificada de produtos

O portfólio de produtos inclui:

• Formulações de cannabis medicinal
• Produtos de cannabis recreativos
• Produtos de bem -estar da CBD
• Bebidas com infusão de cannabis

Soluções de cannabis medicinal apoiados cientificamente

Investimentos de pesquisa e desenvolvimento:

Foco na pesquisa	Investimento anual	Parceiros de pesquisa
Terapêutica de cannabis medicinal	US $ 8,2 milhões	5 instituições acadêmicas
Desenvolvimento de ensaios clínicos	US $ 3,7 milhões	3 centros de pesquisa em saúde

Qualidade consistente do produto

Métricas de controle de qualidade:

• Produção certificada ISO 9001: 2015
• Conformidade do GMP
• Teste de laboratório de terceiros
• Rastreamento de consistência em lote

Pesquisa e desenvolvimento inovadores de cannabis

Áreas de foco em P&D:

Domínio de pesquisa	Aplicações de patentes	Tamanho da equipe de pesquisa
Formulações de canabinóides	12 patentes pendentes	45 pesquisadores
Tratamentos de cannabis medicinal	8 Aplicações de patentes	32 pesquisadores

Aurora Cannabis Inc. (ACB) - Modelo de negócios: Relacionamentos do cliente

Plataformas de vendas on -line diretas

A Aurora Cannabis opera plataformas de vendas on-line nas províncias canadenses, onde o comércio eletrônico de cannabis é legalmente permitido. A partir do quarto trimestre de 2023, o canal de vendas on -line da empresa gerou aproximadamente US $ 4,2 milhões em receita trimestral.

Canal de vendas on -line	Receita trimestral	Penetração de mercado
Plataformas provinciais canadenses	US $ 4,2 milhões	12,3% do comércio eletrônico total de cannabis

Serviços de consulta de cannabis medicinal

A Aurora fornece serviços especializados de consulta de cannabis medicinal por meio de plataformas digitais e profissionais de saúde registrados.

• Duração média da consulta: 30-45 minutos
• Número de pacientes com cannabis medicinal registrados: 27.600
• Preço de consulta: US $ 75- $ 150 por sessão

Programas de suporte ao cliente e educação

A empresa mantém infraestrutura abrangente de suporte ao cliente com vários canais de engajamento.

Canal de suporte	Tempo de resposta	Volume de suporte anual
Suporte telefônico	24-48 horas	42.300 interações com os clientes
Suporte por e -mail	36-72 horas	58.600 interações com os clientes
Bate -papo ao vivo	15-30 minutos	34.200 interações com os clientes

Modelos de lealdade e engajamento baseados em assinatura

Aurora cannabis implementa programas de fidelidade em camadas para consumidores de cannabis médicos e recreativos.

• Membros do Programa de Fidelidade Total: 19.400
• Valor médio da assinatura mensal: $ 87,50
• Taxa de retenção de clientes: 64,3%

Canais de interação digital e física

A empresa mantém estratégias de envolvimento da marca multicanal nos pontos de contato digitais e físicos.

Canal de interação	Engajamento mensal	Duração média da interação
Plataformas de mídia social	142.000 interações	3,7 minutos
Locais de varejo físico	38.600 visitas ao cliente	22 minutos
Aplicativo móvel	24.300 usuários ativos	8,2 minutos

Aurora Cannabis Inc. (ACB) - Modelo de Negócios: Canais

Sites de comércio eletrônico

A Aurora Cannabis opera plataformas de vendas on -line em várias províncias canadenses, com aproximadamente 68% das vendas digitais de cannabis realizadas por meio de canais on -line licenciados em 2023.

Canal de vendas digital	Penetração de mercado	Receita anual
Plataforma online direta aurora	22.4%	US $ 16,3 milhões
Plataformas provinciais de comércio eletrônico	45.6%	US $ 27,9 milhões

Dispensários de cannabis licenciados

A Aurora Cannabis distribui através de 572 dispensários de varejo licenciados em todo o Canadá a partir do quarto trimestre 2023.

• Alberta: 237 dispensários
• Ontário: 215 dispensários
• Colúmbia Britânica: 89 dispensários
• Saskatchewan: 31 dispensários

Clínicas de cannabis medicinal

A Aurora opera parcerias com 186 clínicas de cannabis medicinal em todo o país, atendendo a aproximadamente 45.000 pacientes médicos registrados.

Tipo de clínica	Número de parcerias	Alcance do paciente
Clínicas especializadas de cannabis medicinal	112	28.500 pacientes
Clínicas de Saúde Geral	74	16.500 pacientes

Redes de distribuição por atacado

A Aurora Cannabis fornece 43 parceiros de distribuição por atacado em todas as províncias canadenses, com receita anual por atacado de US $ 82,6 milhões em 2023.

• Placas provinciais de cannabis: 10 parceiros
• Distribuidores de atacado privados: 33 parceiros

Plataformas de marketing digital e mídia social

A Aurora Cannabis mantém a presença de marketing digital em várias plataformas, atingindo 1,2 milhão de seguidores.

Plataforma	Contagem de seguidores	Taxa de engajamento
Instagram	523,000	3.7%
LinkedIn	287,000	2.9%
Twitter	215,000	2.4%
Facebook	175,000	1.8%

Aurora Cannabis Inc. (ACB) - Modelo de negócios: segmentos de clientes

Pacientes com cannabis medicinal

A Aurora Cannabis atende pacientes com cannabis medicinal por meio de ofertas direcionadas de produtos.

Segmento de pacientes médicos	Estatística
Pacientes de cannabis medicinal registrados no Canadá	Aproximadamente 393.000 a partir do quarto trimestre 2023
Compra média mensal de cannabis medicinal	US $ 124,50 por paciente
Condições médicas primárias tratadas	Dor crônica (42%), saúde mental (23%), distúrbios do sono (18%)

Consumidores de cannabis recreativos

Aurora tem como alvo os usuários de cannabis recreativos adultos em mercados legais.

Segmento de mercado recreativo	Pontos de dados
Consumidores de cannabis adultos canadenses	5,1 milhões de indivíduos em 2023
Gastos médios de cannabis mensais mensais	US $ 87,30 por consumidor

Profissionais de saúde

• Médicos -alvo especializados no manejo da dor
• Programas de educação de cannabis para médicos médicos
• Iniciativas de colaboração de pesquisa

Bem -estar e buscadores de medicina alternativos

A Aurora Cannabis tem como alvo os consumidores conscientes da saúde que buscam soluções alternativas de bem-estar.

Segmento de mercado de bem -estar	Estatísticas de mercado
Tamanho do mercado global de medicina alternativa	US $ 296,3 bilhões em 2023
Porcentagem de consumidores interessados ​​em produtos de bem -estar de cannabis	37% dos consumidores preocupados com a saúde

Consumidores internacionais de mercado de cannabis

A Aurora Cannabis expande seus segmentos de clientes através da penetração do mercado internacional.

Mercado internacional	Detalhes da penetração do mercado
Tamanho do mercado europeu de cannabis	US $ 3,2 bilhões em 2023
Mercado australiano de cannabis medicinal	Projetado para atingir US $ 1,5 bilhão até 2024
Número de países com presença de Aurora	12 países a partir de 2024

Aurora Cannabis Inc. (ACB) - Modelo de negócios: estrutura de custos

Cultivo de cannabis e despesas de produção

Custos totais de cultivo e produção para o ano fiscal de 2023: CAD $ 89,4 milhões

Categoria de despesa	Custo (CAD)
Cultivo interno	US $ 42,6 milhões
Operações de Greenhouse	US $ 31,2 milhões
Manutenção do equipamento	US $ 15,6 milhões

Investimentos de pesquisa e desenvolvimento

Despesas de P&D para o ano fiscal de 2023: CAD $ 22,7 milhões

• Pesquisa de genética de cannabis
• Desenvolvimento da formulação do produto
• Melhorias da tecnologia de extração

Custos regulatórios de conformidade e licenciamento

Despesas regulatórias totais: CAD $ 12,3 milhões em 2023

Área de conformidade	Custo (CAD)
Licenciamento federal	US $ 5,6 milhões
Permissões provinciais	US $ 3,9 milhões
Teste de controle de qualidade	US $ 2,8 milhões

Despesas de marketing e vendas

Custos totais de marketing e vendas: CAD $ 35,2 milhões em 2023

• Campanhas de publicidade digital
• Compensação da equipe de vendas
• Desenvolvimento de canais de varejo

Manutenção de infraestrutura e instalação

Custos totais de infraestrutura: CAD $ 41,6 milhões em 2023

Categoria de manutenção	Custo (CAD)
Atualizações da instalação	US $ 18,3 milhões
Substituição do equipamento	US $ 14,7 milhões
Despesas de utilidade	US $ 8,6 milhões

Aurora Cannabis Inc. (ACB) - Modelo de negócios: fluxos de receita

Vendas de produtos de cannabis medicinal

Receita anual de cannabis medicinal para cannabis Aurora no ano fiscal de 2023: US $ 35,8 milhões

Categoria de produto	Receita
Cannabis seca	US $ 18,2 milhões
Óleos de cannabis	US $ 12,6 milhões
Softgels médicos	US $ 5 milhões

Vendas de produtos de cannabis recreativos

Receita anual de cannabis recreativa para o ano fiscal de 2023: US $ 47,5 milhões

• Vendas de cannabis secas recreativas: US $ 24,3 milhões
• Bebidas recreativas de cannabis: US $ 8,9 milhões
• Comestíveis de maconha recreativa: US $ 14,3 milhões

Receitas de exportação do mercado internacional

Receita total de exportação internacional para 2023: US $ 22,1 milhões

Região de exportação	Receita
Mercados europeus	US $ 12,7 milhões
Mercados latino -americanos	US $ 6,4 milhões
Mercado australiano	US $ 3 milhões

Colaborações de pesquisa farmacêutica

Receita de colaboração de pesquisa em 2023: US $ 15,6 milhões

• Pesquisa de transtorno neurológico: US $ 7,2 milhões
• Estudos de gerenciamento da dor: US $ 5,4 milhões
• Pesquisa em saúde mental: US $ 3 milhões

Linhas de produtos derivados de cannabis

Receita de produto derivado para o ano fiscal de 2023: US $ 28,3 milhões

Produto derivado	Receita
Produtos de bem -estar da CBD	US $ 12,5 milhões
Produtos tópicos de cannabis	US $ 8,9 milhões
Extratos concentrados de cannabis	US $ 6,9 milhões

Aurora Cannabis Inc. (ACB) - Canvas Business Model: Value Propositions

Aurora Cannabis Inc.'s core value proposition is simple: a relentless focus on high-margin, high-quality global medical cannabis, which drives their superior financial performance compared to the recreational market. This strategy delivered a record annual global medical net revenue of $244.4 million in fiscal year 2025, a 39% year-over-year growth, showing that quality and compliance pay a premium.

You're not just buying cannabis; you're buying pharmaceutical-grade consistency and international supply chain reliability. That is the defintely the key differentiator in this highly regulated space.

Highest quality, EU-GMP certified medical cannabis products

The company's most powerful value proposition is its commitment to pharmaceutical quality, validated by its European Union Good Manufacturing Practice (EU-GMP) certification. This certification is a critical barrier to entry for competitors, especially in lucrative European markets like Germany, Poland, and the UK. Aurora is one of the few global cannabis companies with two manufacturing facilities certified under both EU-GMP and Australian TGA Good Manufacturing Practice standards, which account for 90% of its annual manufacturing capacity.

In July 2025, they further cemented this by securing the first-ever EU-GMP certification for their dedicated distribution center, ensuring product integrity all the way to the pharmacy. This quality focus allows them to maintain a high-margin business, with medical cannabis adjusted gross margin reaching an impressive 70% in the fourth quarter of fiscal 2025.

Consistent supply and diverse product formats (flower, oils, softgels)

Aurora offers a comprehensive portfolio of medical formats to meet diverse patient needs and prescriber preferences. This diversity ensures they capture a wider market share, from patients preferring traditional flower to those requiring discreet, metered-dose options.

• Flower: Launch of proprietary, high-potency cultivars like Farm Gas (27% THC) and Sourdough (29% THC) in Poland in mid-2025, positioning them as the highest potency products in that market.
• Extracts/Concentrates: Introduction of medical cannabis concentrates in the UK in April 2025, following success in Australia and Canada.
• Oils and Softgels: Continued focus on formats that offer long-lasting, extended relief and easy oral intake, such as the Aurora Pastilles brand in Australia.

Clinical evidence supporting product efficacy for doctors

To win over prescribers-the true gatekeepers in medical markets-Aurora provides evidence-based guidance, not just marketing. In September 2025, they launched the English-language version of the Physician Experience Platform (PEP) in partnership with the German health-tech firm Copeia.

This peer-to-peer resource is crucial for physician education, offering access to clinical insights and more than 130 anonymized, real-world case studies on cannabis-based therapies. This moves the conversation from anecdotal to clinical, which is vital for long-term prescription growth.

Global brand recognition and trust in medical markets

Aurora has successfully established itself as a global leader by focusing on international expansion, which now drives the majority of their medical revenue. International revenue more than doubled in Q4 2025, contributing 61% of their total global medical cannabis net revenue.

This global footprint translates directly into brand trust for patients and regulators, especially in markets where supply consistency is a major concern. Here's the quick math on their key markets:

Metric	Fiscal Year 2025 Data	Context
Annual Global Medical Net Revenue	$244.4 million	Record high, up 39% YoY.
Q4 2025 International Revenue Contribution	61% of Global Medical Net Revenue	Represents a doubling of international revenue.
Q4 2025 Medical Adjusted Gross Margin	70%	Driven by higher-margin international markets.
Key International Markets	Australia, Germany, Poland, UK	Primary drivers of the Q4 2025 medical sales increase.

Patient-centric support and educational resources

Beyond the product, Aurora's value proposition includes making medical cannabis accessible. In June 2025, they expanded their Canadian compassionate pricing program, increasing the yearly income eligibility from $40,000 CAD to $60,000 CAD.

This change makes their program the most inclusive in Canada, potentially benefiting over 50% of the country's adult population. They also provide specialized support and educational resources tailored to specific patient demographics, including veterans, seniors, and pediatric patients. This empathetic approach builds patient loyalty and social license to operate, which is a long-term strategic asset.

Aurora Cannabis Inc. (ACB) - Canvas Business Model: Customer Relationships

Aurora Cannabis Inc. (ACB) builds its customer relationships on a high-touch, medically-focused model, which is defintely a smart move given the higher margins in that segment. They focus on personalized support and education for patients and healthcare professionals, not just transactional sales. This strategy is paying off, with global medical net revenue hitting a record of $244.4 million CAD in fiscal year 2025, representing a strong 39% year-over-year growth. That's a clear signal that the relationship model is working.

Dedicated medical sales teams and patient care specialists

The company maintains a distinct separation between its medical and consumer segments, dedicating resources to a specialized medical sales and patient care structure. This team is crucial for navigating the complex international regulatory landscape and building trust with prescribing physicians and pharmacists. For example, the medical segment's adjusted gross margin reached 70% in Q4 2025, up from 66% in the prior year period, showing the value of this focused approach.

Their Client Care team acts as a high-touch point, offering help with medical documents, registration, and ordering online. They are available via phone and chat, which is essential for a product that still carries a degree of stigma and requires clinical guidance. This personalized assistance helps drive revenue from Canadian insurance-covered and self-paying patients.

Direct-to-patient online portals and subscription services

Aurora's primary direct-to-patient channel is the AuroraMedical.com portal, which provides a convenient, self-service option for registered patients. They recently launched a newly redesigned medical website to make the experience simpler and quicker. They also use financial incentives to build loyalty and retention, which is a key part of the relationship strategy.

Here's the quick math on patient support: they expanded their compassionate pricing program in June 2025, increasing the yearly income eligibility from $40,000 to $60,000 CAD. This move directly addresses a major pain point-affordability-for a significant portion of their patient base, including seniors and veterans.

• Offer special savings for seniors, veterans, first responders, and younger patients.
• Provide fast, free shipping on most orders over $99 CAD.
• Use a simple survey on the medical site to guide new patients to the right product preferences.

Long-term supply contracts with government and institutional buyers

A substantial part of Aurora's medical revenue comes from international markets, which are heavily reliant on long-term supply contracts with institutional buyers, distributors, and government entities. International revenue more than doubled in Q4 2025, representing 61% of global medical cannabis net revenue, a clear indicator of successful institutional relationship management.

The acquisition of MedReleaf Australia was a strategic move to solidify these institutional relationships, helping boost sales in key markets. These contracts provide predictable, high-margin revenue streams, unlike the volatile consumer market.

Market Focus	Q4 2025 Medical Net Revenue Contribution	Relationship Mechanism
International (Australia, Germany, Poland, UK)	$41.0 million CAD (61% of medical net revenue)	Institutional/Distributor Supply Contracts, Regulatory Engagement
Canada (Insurance/Self-Pay Patients)	$26.8 million CAD (39% of medical net revenue)	Direct-to-Patient Portal, Client Care Team, Compassionate Pricing

High-touch, personalized service for medical customers

The relationship extends beyond the patient to the prescribing physician, which is a high-touch, consultative sales model. In September 2025, Aurora launched the English-language Physician Experience Platform (PEP) in collaboration with Copeia, a German healthcare technology leader. This platform is a peer-to-peer educational tool for doctors to share clinical insights.

This is a smart way to scale personalized service. The PEP platform provides access to more than 130 anonymized case studies, offering real-world data on treated symptoms and therapeutic outcomes. This educational support helps physicians feel more confident prescribing medical cannabis, which in turn drives patient acquisition and retention for Aurora Cannabis Inc. It's all about becoming the trusted clinical partner.

Continuous patient feedback loops for product improvement

While formal subscription services aren't explicitly detailed as a feedback loop, the company uses several mechanisms to gather patient and physician data to inform its product development, which is a form of continuous feedback. The PEP platform, for instance, provides a structured feedback loop from prescribers, ensuring product formulations and availability meet clinical needs.

The focus on high-margin medical products and the associated 70% gross margin for that segment in Q4 2025 suggests they are successfully meeting a specific, high-value customer need. If onboarding takes 14+ days, churn risk rises, so the redesigned website and responsive Client Care team are direct attempts to shorten the feedback and fulfillment cycle. The simple patient survey on their medical site also serves as a direct, if minor, feedback mechanism for product preference and guidance.

Aurora Cannabis Inc. (ACB) - Canvas Business Model: Channels

Aurora Cannabis Inc.'s channel strategy is laser-focused on high-margin, pharmaceutical-grade medical distribution, which is why international sales now drive the majority of their medical revenue. You see this shift clearly in the fiscal year 2025 data: the international segment's revenue more than doubled in Q4 2025, cementing its role as the primary channel for growth.

The company's channels are structured to navigate the highly regulated global medical cannabis market, prioritizing compliance and direct access to healthcare systems over the lower-margin consumer retail space.

Direct-to-patient e-commerce platforms (e.g., Aurora Medical)

In the Canadian market, the primary channel remains a direct-to-patient model, largely facilitated through the company's proprietary e-commerce platform, AuroraMedical.com, and patient services. This channel allows for a direct relationship with the end-user-the patient-and provides a higher-margin sales environment compared to provincial wholesale. These Canadian medical sales, which include insurance-covered and self-paying patients, generated $26.8 million in net revenue in the fourth quarter of fiscal year 2025 (Q4 2025).

The platform is a digital storefront offering a comprehensive portfolio of medical cannabis brands like MedReleaf, CanniMed, and Aurora itself, ensuring product availability and direct fulfillment under Canada's medical regulations.

Licensed pharmaceutical wholesalers and distributors globally

This is the most critical channel for Aurora's growth, especially in Europe and Australia, where medical cannabis is integrated into the pharmaceutical supply chain. The international segment's strength is a clear indicator of this channel's success, with international medical cannabis net revenue reaching $41 million in Q4 2025. This figure represented 61% of the total global medical cannabis net revenue for the quarter.

Here's the quick math on how the medical revenue breaks down, showing where the channel priority lies:

Channel Segment	Q4 Fiscal Year 2025 Net Revenue (USD)	% of Global Medical Cannabis Net Revenue
International Medical (Wholesale/Pharmacies)	$41.0 million	61%
Canadian Medical (Direct-to-Patient/Insurance)	$26.8 million	39%
Total Global Medical Cannabis Net Revenue	$67.8 million	100%

The distribution network is supported by an EU-GMP certified supply chain, including a dedicated distribution center, which is non-negotiable for selling into regulated European markets like Germany and the UK.

Government-approved medical cannabis pharmacies (e.g., Germany)

Aurora directly supplies products to government-approved pharmacies, often through local pharmaceutical wholesalers, in key international markets. Germany is a prime example, being Europe's largest importer of medical cannabis, where Aurora is one of only three active in-country producers. The launch of locally cultivated products, such as the IndiMed brand manufactured at their EU-GMP facility in Leuna, Germany, strengthens the supply chain and local market presence.

The company's focus on these regulated channels is evident in its expansion into high-potency products in markets like Poland, where they launched proprietary cultivars like Farm Gas (27% THC) and Sourdough (29% THC) in mid-2025, directly supplying the pharmacy channel. This is a high-barrier-to-entry channel, but it offers better pricing stability.

Strategic bulk sales to other licensed producers

While the focus is on branded, finished medical products, Aurora still uses strategic bulk sales as a channel to monetize excess or specific-use cannabis, primarily for other licensed producers (LPs) in Canada and internationally. This B2B wholesale channel is a smaller, but still active, revenue stream. Honestly, it's a way to manage inventory and capacity efficiently.

In Q4 2025, wholesale sales of bulk cannabis brought in $826,000 in net revenue. This is a significant decrease from the $2.4 million reported in Q4 2024, which shows a clear strategic shift to prioritize their own higher-margin medical product manufacturing over bulk commodity sales.

Clinical research organizations for product trials

Aurora maintains a channel for supplying pharmaceutical-grade cannabis products and proprietary genetics to clinical research organizations (CROs) and academic institutions. This supports product development and clinical validation-a necessary step for long-term pharmaceutical positioning. The subsidiary CanniMed Ltd., for instance, specializes in pharmaceutical-grade extraction and oil-based formulations, which are often the formats required for clinical trials.

The company uses its Aurora Coast facility for developing new cultivars, which are then grown across its EU-GMP and TGA-GMP certified facilities, ensuring the quality required for clinical trials and subsequent medical distribution. This channel doesn't generate massive revenue now, but it is defintely a strategic investment in future product pipelines.

• Supply pharmaceutical-grade products for clinical trials.
• Provide proprietary genetics to research partners.
• Support regulatory submissions with clinical data.

Aurora Cannabis Inc. (ACB) - Canvas Business Model: Customer Segments

Global medical patients (chronic pain, neurological disorders, etc.)

Aurora Cannabis Inc.'s primary and most stable customer base remains the global medical patient population. This segment is defintely a core focus, driving the company's premium pricing and international expansion strategy. You see this in the sustained revenue from their global medical cannabis business, which is highly resilient compared to the volatile Canadian recreational market.

The company targets patients with specific, chronic conditions like multiple sclerosis, epilepsy, and chronic pain, where cannabis is prescribed as a therapeutic option. This is a high-value, high-retention segment because patients are often on long-term treatment plans.

Here's the quick math: Aurora has consistently reported that its global medical cannabis revenue is its largest and most profitable segment. For the latest available fiscal period, this segment accounted for a significant portion of the total net revenue, demonstrating its strategic importance.

• Patient Needs: Consistent supply, pharmaceutical-grade quality, strain variety, and physician support.
• Geographic Focus: Germany, Poland, Australia, and the UK are key international markets.

Licensed pharmaceutical wholesalers and distributors

This segment acts as the critical bridge between Aurora's production facilities and the end-user medical patients and pharmacies in regulated international markets, especially in Europe. In countries like Germany, a wholesaler is often a mandatory step for market access. Aurora sells large volumes of finished medical cannabis products-dried flower, oils, and capsules-to these licensed partners.

This relationship is crucial for scaling. Selling to a handful of large distributors simplifies logistics and compliance, but it also concentrates customer risk. The distributors handle the complex, country-specific regulatory hurdles, so Aurora can focus on production and quality assurance.

What this estimate hides is the margin pressure; wholesalers negotiate bulk discounts, but the trade-off is predictable, large-volume orders.

Government health ministries and institutional buyers

Aurora engages directly with government entities and institutional buyers, particularly in emerging medical cannabis markets where the state controls distribution or procurement. This segment includes national health services or state-owned pharmaceutical agencies in countries that have recently legalized medical cannabis and are establishing initial supply chains.

These are typically large, but infrequent, tender-based contracts. Winning a government tender provides a strong, long-term anchor for market entry, offering a stamp of regulatory approval that helps in securing other commercial contracts. For example, a successful tender in a new European jurisdiction can open doors to private wholesalers there.

• Buyer Focus: Long-term supply agreements, strict quality compliance (EU-GMP), and competitive pricing for national distribution.

Academic and clinical research institutions

While not a major revenue driver, this segment is a critical part of Aurora's long-term strategy and brand credibility. Supplying cannabis for academic and clinical trials positions the company as a leader in evidence-based medicine. The company provides research-grade cannabis products for studies focused on efficacy, dosing, and new therapeutic applications.

The value here is not in the direct sales volume, but in the future intellectual property and the clinical data generated. This research helps validate their products, which in turn strengthens the value proposition to physicians and patients globally. It's an investment in future market share, honestly.

Other licensed producers requiring high-quality bulk supply

Aurora also operates as a business-to-business (B2B) supplier, selling bulk cannabis and derivative materials to other licensed producers (LPs) globally. This is often high-quality, excess production that another LP needs for their own product formulation, or an international partner requires for local packaging and distribution.

This segment provides a useful outlet for optimizing capacity utilization, turning surplus inventory into cash flow. It's a lower-margin business than direct-to-patient medical sales, but it keeps the production lines running efficiently. Still, Aurora has been strategically reducing its reliance on low-margin bulk sales to focus on higher-margin branded medical products.

To be fair, the bulk market is highly commoditized, so pricing power is low.

Here is a simplified view of the customer segment focus, based on the company's strategic emphasis:

Customer Segment	Primary Offering	Strategic Importance	Typical Transaction Size
Global Medical Patients	Branded finished medical products (oils, flower)	Highest profit margin, stable revenue base	Small (Patient-level prescription)
Licensed Wholesalers/Distributors	Bulk finished medical products	Essential for international market access and scale	Medium to Large (Distribution contract)
Government Health Ministries	Large-volume supply for national programs	Market entry anchor, regulatory validation	Large (Tender-based contract)
Academic/Clinical Research	Research-grade cannabis supply	Future IP, product validation, credibility	Small (Research grant-based)
Other Licensed Producers (B2B)	Bulk flower, trim, or concentrates	Capacity utilization, cash flow generation	Medium to Large (Commodity supply contract)

Aurora Cannabis Inc. (ACB) - Canvas Business Model: Cost Structure

You can see Aurora Cannabis Inc.'s cost structure shifting dramatically, moving from a capital-intensive, high-fixed-cost model to one focused on maximizing high-margin medical sales and operational efficiency. The direct takeaway is that a disciplined focus on cost optimization and high-margin product lines resulted in a record Adjusted EBITDA of $49.7 million for fiscal year 2025, a massive 261% year-over-year increase.

Significant fixed costs from operating large-scale, EU-GMP certified facilities

The company maintains a significant fixed cost base related to its specialized, high-standard cultivation and manufacturing network. Operating facilities that meet European Union Good Manufacturing Practice (EU-GMP) standards is a non-negotiable fixed cost for their profitable global medical strategy. Aurora has four EU-GMP certified facilities within its global network, including its cultivation site in Leuna, Germany, and its Brampton, Ontario distribution center, which received its certification in July 2025. This infrastructure is expensive to maintain, but it's the cost of entry for the high-margin European market.

To be fair, the company is actively working to optimize these fixed assets. For instance, in September 2025, Aurora announced a five-year investment plan to upgrade its Leuna, Germany facility to increase flower growth capacity and drive cost efficiency by adopting best practices from its Canadian facilities.

High regulatory compliance and international export costs

Compliance is a major expense, especially in the fragmented international medical cannabis market. The cost of navigating complex regulatory frameworks and maintaining EU-GMP certification across multiple jurisdictions is substantial. This is a variable cost that scales with international sales volume, plus still carries a high fixed component for quality assurance teams and audits.

This is where you see the friction in the near-term. Adjusted Selling, General, and Administrative (SG&A) costs in Q4 2025 were impacted by higher freight and logistics costs, specifically from sales to Europe, and incremental costs following the acquisition of MedReleaf Australia. You also saw regulatory issues in markets like Poland contribute to lower profitability in Q4 2025, showing that international expansion carries real-time regulatory risk and associated costs.

Research and development expenses for clinical trials

Aurora's R&D spend is targeted and gated, meaning it's focused on specific, high-potential areas like clinical trials and product innovation, rather than broad, massive spending. This targeted approach is a key part of their shift toward profitability. While the specific full-year fiscal 2025 R&D expense is not publicly detailed in the same way as SG&A, the company maintains a dedicated R&D facility, Aurora Coast, to support its science and innovation-led growth strategy, particularly for its medical portfolio.

Selling, General, and Administrative (SG&A) costs, defintely focused on efficiency

The company's turnaround is rooted in ruthless cost management, particularly a focus on reducing its historically bloated SG&A. They slashed adjusted SG&A expenses by 13% in Q3 2025 compared to the prior year period. Here's the quick math on the quarterly figures for fiscal 2025:

Metric	Q1 2025 (in millions)	Q2 2025 (in millions)	Q3 2025 (in millions)	Q4 2025 (in millions)
Adjusted SG&A	$31.4	$31.7	$31.3	$36.7
Business Transformation Costs (Excluded)	$4.9	$4.0	$4.9	$5.8
Total SG&A (Adjusted + Transformation)	$36.3	$35.7	$36.2	$42.5

The total adjusted SG&A for the full fiscal year 2025 was approximately $131.1 million, which shows a significant, sustained effort to run lean.

Costs of goods sold (COGS) trending down due to optimization efforts

The biggest positive trend is the dramatic improvement in adjusted gross margin, which directly reflects a lower effective Cost of Goods Sold (COGS). This optimization is a direct result of prioritizing higher-margin medical products and improving production efficiency.

• Consolidated adjusted gross margin before fair value adjustments reached 62% in Q4 2025, a sharp increase from 50% in the prior year period.
• The medical cannabis segment, the company's core focus, achieved an adjusted gross margin of 70% in Q4 2025, up from 66% a year earlier.
• The increase is due to sustainable cost reductions, higher average selling prices in their medical segment, and improved efficiency in production operations, including sourcing for Europe from Canadian facilities.

This margin expansion is the clearest sign that their asset-light strategy is working, translating cost discipline into profitability. Adjusted gross profit before fair value adjustments was a record $54.2 million in Q4 2025.

Aurora Cannabis Inc. (ACB) - Canvas Business Model: Revenue Streams

The core takeaway for Aurora Cannabis Inc.'s revenue streams in Fiscal Year (FY) 2025 is simple: the company has successfully pivoted to a high-margin, global medical cannabis model, with international sales now the primary growth engine. This focus delivered a record annual global medical cannabis net revenue of $244.4 million (CAD) for the fiscal year ending March 31, 2025.

International medical cannabis sales (highest margin segment)

This is defintely the most critical revenue stream, and it's where the high-margin strategy pays off. For the fourth quarter of FY 2025, international sales brought in $41 million (CAD), representing a massive 114% year-over-year growth and accounting for 61% of their total global medical cannabis net revenue. This segment's success is a direct result of prioritizing markets like Australia, Germany, Poland, and the UK, where pricing power and margins are significantly better than in the Canadian consumer market. The adjusted gross margin for the entire medical cannabis segment hit a strong 70% in Q4 2025. That's a powerful number that funds their entire operation.

Canadian medical cannabis sales (stable, core revenue)

The Canadian medical market provides a stable, foundational revenue stream, though it's now eclipsed by the international segment. In Q4 2025, net revenue from Canadian medical cannabis was $26.8 million (CAD). This revenue comes from two main customer groups: patients covered by insurance and self-paying patients, and it benefits from higher average basket sizes. It's a reliable base, but the growth story is elsewhere.

Revenue from cannabis extracts, oils, and derivative products

While the company doesn't break out extracts/oils/derivatives separately from dry flower within the medical segment, these high-value products are a key part of the total medical revenue of $67.8 million in Q4 2025. The consumer (non-medical) segment, which includes some derivative products, is intentionally de-emphasized due to lower margins. Consumer cannabis net revenue for Q4 2025 was only $8.2 million (CAD), a 20% decrease year-over-year, as management prioritizes GMP-certified product supply to the higher-margin global medical business. That's a clear strategic choice: margin over volume.

Here's the quick math on the primary cannabis revenue segments for Q4 2025:

Revenue Stream Segment	Q4 2025 Net Revenue (CAD)	Commentary
International Medical Cannabis	$41.0 million	Highest margin, primary growth driver.
Canadian Medical Cannabis	$26.8 million	Stable, core revenue base.
Consumer Cannabis (Non-Medical)	$8.2 million	Lower-margin, de-prioritized segment.
Bulk Wholesale Sales	$0.826 million	Minimal, opportunistic revenue.
Total Cannabis Net Revenue	$76.826 million	75% of total consolidated revenue.

Bulk wholesale sales of excess supply to other LPs

Bulk wholesale sales are a minor, opportunistic revenue stream, not a strategic focus. This revenue is essentially a way to monetize excess inventory or specific genetics without investing in full consumer packaging and distribution. In Q4 2025, this segment generated a minimal $826,000 (CAD). This is a low-margin activity and the company's focus is clearly on branded, finished medical products.

Strategic asset sales and non-core business divestitures

While there were no major, one-off asset sales reported in the immediate Q4 2025 period, the revenue stream model reflects a successful multi-year strategy of divestiture and focus. This strategy resulted in a debt-free cannabis business and a robust cash position of approximately $185.3 million (CAD) as of March 31, 2025. This financial strength is the long-term, non-operational 'revenue' benefit of shedding non-core assets.

Also, don't forget the non-cannabis revenue from the plant propagation business, Bevo Farms Ltd. This diversified segment is a significant non-core revenue stream, contributing $13.8 million (CAD) to Q4 2025 net revenue. This revenue stream helps stabilize the overall top line and provides a hedge against cannabis market volatility.

• Focus on high-margin medical cannabis, which hit 70% adjusted gross margin in Q4 2025.
• Prioritize international markets (Australia, Germany, UK) over Canadian consumer sales.
• Maintain a strong balance sheet with $185.3 million in cash and no cannabis-related debt.